Embracing the Promise of Patient-Centered Biotechnology
James Geraghty, investor and executive, discusses his new book “Inside the Orphan Drug Revolution,” his concerns about the changing rare disease policy landscape, and why he believes it's essential for companies to take a patient-centric approach to drug development.